Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...

Ocugen (NASDAQ:OCGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports.

Ocugen (NASDAQ:OCGN) said it has received a positive opinion from European Medicines Agency regulators for Advanced Therapy Medicinal Product classification for its gene therapy OCU400 in the ...

Ocugen (OCGN) announced that the European Commission has provided a positive opinion from the EMA’s, or European Medicines Agency’s, Committee for Advanced Therapies for OCU400 Advanced ...

As of 10:47:49 a.m. EST. Market Open. MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company ...

16:16 EST Ocugen (OCGN) files to sell 57.54M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now ...

(RTTNews) - Ocugen, Inc. (OCGN) Monday said that the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) has provided a positive opinion for Advanced Therapy Medicinal Product ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...

Shares of Ocugen Inc. OCGN advanced 5.59% to $0.75 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...

At close: 14 November at 4:00 pm GMT-5 ...